Shots :
- Celltrion has submitted BLA to the US FDA seeking approval for CT-P47 in both IV and SC route of administrations based on the P-III study
- The P-III study assesses the safety, efficacy, PK, and immunogenicity of CT-P47 vs Actemra for treating moderate to severe active rheumatoid arthritis with inadequate response to methotrexate up to wk. 52
- CT-P47 is a recombinant humanized mAb which targets interleukin 6 (IL-6) receptor indicated for treating rheumatoid arthritis
Ref: Coherus Biosciences & Sandoz | Image: Coherus Biosciences & Sandoz| Press Release
Related News:- Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
